clinical trial · NCT06864624
Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
Tang-Du Hospital·phase2·recruiting·n = 27
NSCLCSunvozertinib
brief summary
This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation.
started
Feb 18, 2025
primary completion
Dec 1, 2026
completion
Jun 1, 2029
last updated
Jul 25, 2025
official title
Sunvozertinib as Neoadjuvant and Adjuvant Therapy in Stage II-IIIB Non-small-cell Lung Cancer Patients With EGFR Exon 20 Insertion Mutation: a Single-arm, Phase 2 Study (WU-KONG20)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol